Chemoresistance : intricate interplay between breast tumor cells and adipocytes in the tumor microenvironment

Mentoor, Ilze ; Engelbrecht, Anna-Mart ; Van Jaarsveld, Paul J. ; Nell, Theo (2018-12-11)

CITATION: Mentoor, I., et al. 2018. Chemoresistance : intricate interplay between breast tumor cells and adipocytes in the tumor microenvironment. Frontiers in Endocrinology, 9:758, doi:10.3389/fendo.2018.00758.

The original publication is available at http://journal.frontiersin.org/journal/endocrinolog

Publication of this article was funded by the Stellenbosch University Open Access Fund.

Article

Excess adipose tissue is a hallmark of an overweight and/or obese state as well as a primary risk factor for breast cancer development and progression. In an overweight/obese state adipose tissue becomes dysfunctional due to rapid hypertrophy, hyperplasia, and immune cell infiltration which is associated with sustained low-grade inflammation originating from dysfunctional adipokine synthesis. Evidence also supports the role of excess adipose tissue (overweight/obesity) as a casual factor for the development of chemotherapeutic drug resistance. Obesity-mediated effects/modifications may contribute to chemotherapeutic drug resistance by altering drug pharmacokinetics, inducing chronic inflammation, as well as altering tumor-associated adipocyte adipokine secretion. Adipocytes in the breast tumor microenvironment enhance breast tumor cell survival and decrease the efficacy of chemotherapeutic agents, resulting in chemotherapeutic resistance. A well-know chemotherapeutic agent, doxorubicin, has shown to negatively impact adipose tissue homeostasis, affecting adipose tissue/adipocyte functionality and storage. Here, it is implied that doxorubicin disrupts adipose tissue homeostasis affecting the functionality of adipose tissue/adipocytes. Although evidence on the effects of doxorubicin on adipose tissue/adipocytes under obesogenic conditions are lacking, this narrative review explores the potential role of obesity in breast cancer progression and treatment resistance with inflammation as an underlying mechanism.

Please refer to this item in SUNScholar by using the following persistent URL: http://hdl.handle.net/10019.1/105556
This item appears in the following collections: